-$0.23 Earnings Per Share Expected for Quanterix Corp (QTRX) This Quarter
Brokerages predict that Quanterix Corp (NASDAQ:QTRX) will announce earnings per share (EPS) of ($0.23) for the current quarter, Zacks reports. Two analysts have made estimates for Quanterix’s earnings, with estimates ranging from ($0.27) to ($0.19). Quanterix reported earnings per share of ($1.06) in the same quarter last year, which suggests a positive year-over-year growth rate of 78.3%. The firm is expected to announce its next earnings report on Monday, March 18th.
According to Zacks, analysts expect that Quanterix will report full year earnings of ($1.21) per share for the current fiscal year, with EPS estimates ranging from ($1.28) to ($1.13). For the next year, analysts anticipate that the business will post earnings of ($0.98) per share, with EPS estimates ranging from ($0.99) to ($0.96). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side analysts that cover Quanterix.
Quanterix (NASDAQ:QTRX) last issued its earnings results on Wednesday, November 7th. The company reported ($0.35) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.28) by ($0.07). The business had revenue of $10.59 million for the quarter, compared to analyst estimates of $9.57 million. Quanterix had a negative return on equity of 52.35% and a negative net margin of 88.72%.
In other news, CFO Joseph Driscoll sold 25,000 shares of the business’s stock in a transaction dated Thursday, November 15th. The stock was sold at an average price of $16.60, for a total transaction of $415,000.00. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Chairman E Kevin Hrusovsky sold 2,829 shares of the business’s stock in a transaction dated Thursday, November 1st. The stock was sold at an average price of $17.97, for a total value of $50,837.13. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 77,764 shares of company stock worth $1,341,815. Company insiders own 31.60% of the company’s stock.
Several large investors have recently added to or reduced their stakes in the company. FMR LLC grew its holdings in shares of Quanterix by 0.4% during the third quarter. FMR LLC now owns 1,325,749 shares of the company’s stock worth $28,398,000 after purchasing an additional 5,359 shares during the last quarter. Jennison Associates LLC boosted its holdings in Quanterix by 1.8% in the second quarter. Jennison Associates LLC now owns 351,831 shares of the company’s stock valued at $5,052,000 after acquiring an additional 6,170 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in Quanterix by 33.1% in the third quarter. Bank of New York Mellon Corp now owns 28,855 shares of the company’s stock valued at $618,000 after acquiring an additional 7,169 shares during the last quarter. Acadian Asset Management LLC bought a new stake in Quanterix in the second quarter valued at approximately $117,000. Finally, Teachers Advisors LLC bought a new stake in Quanterix in the third quarter valued at approximately $219,000. Institutional investors own 49.62% of the company’s stock.
NASDAQ QTRX traded up $0.31 during trading on Friday, hitting $19.50. 105,799 shares of the company’s stock were exchanged, compared to its average volume of 97,918. The company has a current ratio of 4.11, a quick ratio of 3.76 and a debt-to-equity ratio of 0.16. The company has a market cap of $408.22 million and a price-to-earnings ratio of -2.35. Quanterix has a fifty-two week low of $13.00 and a fifty-two week high of $24.81.
Quanterix Corporation, a life sciences company, develops and markets ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific. It develops Simoa HD-1 Analyzer, a sensitive protein detection platform, which analyzes approximately six biomarkers per test; and Quanterix SR-X, which utilizes the same technology and assay kit as the Simoa HD-1 Analyzer.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Quanterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quanterix and related companies with MarketBeat.com's FREE daily email newsletter.